Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma

J. M. Versluis,E. P. Hoefsmit,H. Shehwana,P. Dimitriadis,J. Sanders,A. Broeks,C. U. Blank

DOI: https://doi.org/10.1007/s00262-023-03581-6

IF: 6.63

2024-01-29

Cancer Immunology Immunotherapy

Abstract:Immune checkpoint inhibition (ICI) has improved patients' outcomes in advanced melanoma, often resulting in durable response. However, not all patients have durable responses and the patients with dissociated response are a valuable subgroup to identify mechanisms of ICI resistance.

oncology,immunology

What problem does this paper attempt to address?

### What problem does this paper attempt to solve?

This paper aims to explore the tumor characteristics of dissociated response to immune checkpoint inhibitors (ICI) in patients with advanced melanoma. Specifically, the researchers hope to analyze patients with partial lesion regression and progression in other lesions after ICI treatment, and reveal the specific mechanisms of resistance to ICI in these patients.

#### Research background

Immune checkpoint inhibitors (ICI) have shown the effect of improving patient survival rates in a variety of advanced malignancies and have become one of the standard treatment regimens, especially in patients with stage IV melanoma. However, not all patients can achieve long - lasting efficacy, and some patients will have a dissociated response, that is, some tumor lesions shrink or disappear, while other lesions continue to grow or newly occur. This heterogeneous clinical response pattern can be spatial (different responses in different lesions) or temporal (different responses at different time points). Understanding the biological mechanisms behind these dissociated responses is crucial for designing more effective treatment strategies.

#### Research objectives

The main objective of this study is to evaluate the histopathological, DNA, and RNA characteristics by comparing the regressed and progressive tumor lesions in the same patient, in order to reveal the potential mechanisms of dissociated response under ICI treatment. Specifically, the researchers hope to solve the problem in the following aspects:

1. **Evaluate immune cell infiltration**: Compare the number of CD8+ T cells and PD - L1 expression in regressed and progressive lesions.
2. **Analyze gene mutations**: Detect key gene mutations that may affect antigen presentation and immune escape, such as B2M, PTEN, POLE, etc.
3. **Evaluate tumor mutation burden (TMB)**: Compare the TMB levels between different lesions to understand its relationship with the efficacy of ICI.
4. **Explore the immune microenvironment**: Analyze the changes in the IFNγ signaling pathway and other immune - related gene expressions to reveal the possible mechanisms of immune escape.

Through these analyses, the researchers hope to provide new insights into understanding the ICI resistance mechanisms and provide a theoretical basis for the development of more effective treatment strategies in the future.